We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Epidermolysis bullosa aquisita following immune‐checkpoint inhibitor treatment for metastatic melanoma.
- Authors
O'Connor, Jane; Zhang, Shuai; Galante, Joao R.; Mee, John; Semkova, Kristina; Parkar, Rosemeen; Groves, Richard
- Abstract
A case of epidermolysis bullosa aquisita following immunotherapy for melanoma. Cutaneous immune-related AEs (irAEs) are commonly reported following immune checkpoint inhibitor treatment.1 Subepidermal blistering disorders arise due to antibody-mediated attack on proteins at the dermoepidermal junction, and typically cause tense blisters. Epidermolysis bullosa aquisita following immune-checkpoint inhibitor treatment for metastatic melanoma.
- Subjects
IMMUNE checkpoint inhibitors; BULLOUS pemphigoid; EPIDERMOLYSIS bullosa; DRUG side effects; IMMUNE checkpoint proteins; MELANOMA
- Publication
Clinical & Experimental Dermatology, 2022, Vol 47, Issue 6, p1198
- ISSN
0307-6938
- Publication type
Article
- DOI
10.1111/ced.15161